VEGF-C、VEGFR-3在骨髓增生异常综合征患者中的表达及临床意义  

Expression and clinical significance of VEGF-C and VEGFR-3 in patients with myelodysplastic syndromes

作　　者：刘婷婷[1] 柯波[1] 刘彬[2] 郑永亮[2] 曾俊权[2] 

机构地区：[1]江西省人民医院血液科,南昌330006 [2]井冈山大学附属医院血液科,吉安343000

出　　处：《江西医药》2015年第12期1379-1381,共3页Jiangxi Medical Journal

摘　　要：目的探讨血管内皮生长因子-C（VEGF-C）以及其受体VEGFR-3在骨髓增生异常综合征（MDS）患者中的表达及临床意义。方法选取2013年1月-2015年1月井冈山大学附属医院血液科住院的76例MDS患者纳入试验组,另将同期住院的42例非恶性血液病患者纳入对照组,采用免疫组织化学法检测所有患者骨髓活组织中VEGF-C及VEGFR-3表达水平,分析其在骨髓增生异常综合征患者中的临床意义。结果试验组患者骨髓中VEGF-C、VEGF-3阳性率（59.2%、55.3%）明显高于对照组（9.5%、4.8%）,两组间表达差异具有高度显著性意义（χ~2=27.50、29.50,P〈0.01）;不同IPSS危度的MDS患者,VEGF-C及VEGF-3阳性表达均存在高度显著性差异（χ~2=14.92、11.28,P〈0.01）,VEGF-C和VEGF-3的阳性率均随着MDS患者IPSS危度的加重而增加。结论 VEGF-C及VEGFR-3在MDS患者中阳性表达率较高,且与MDS的危险度分级呈正相关,因此推测有可能作为抗血管生成药物的分子标靶用于治疗MDS。Objective To explore the expression and clinical significance of vascular endothelial growth factor-C （VEGF-C） and its receptor VEGFR-3 in patients with myelodysplastic syndromes （MDS）. Methods 76 patients with MDS who were hospital- ized in the Department of Hematology of Jinggangshan University Hospital from January 2015 to January 2013 were included in the experimental group, and 42 patients with non malignant hematological diseases were included in the control group. The expression level of VEGFR-3 and VEGF-C was detected by the method of immunohistochemical,and then discuss the clinical significance in MDS patients. Results The positive rate of VEGF-C and VEGF-3 expression in the experimental group （59.2% ,55.3%） / was significantly higher than the control group（9.5% ,4.8%）,and there was significantly difference between two groups （x^2=27.50, 29.50,P〈0.01）. The study also found that the positive rate of VEGF-C,VEGF-3 expression increaseed along with IPSS score in MDS patients, and the significant difference of the positive rate also appeared in patients with different IPSS score （x^2=14.92,11. 28,P〈0.01 ）. Conclusion The positive rate of VEGF-C and VEGF-3 expression was higher in MDS patients,and was positively correlated with the risk degree of MDS, hence VEGF-C and VEGF-3 can be used as the target of anti angiogenic drugs.

关 键 词：VEGF-C VEGFR-3 骨髓增生异常综合征 

分 类 号：R551.3[医药卫生—血液循环系统疾病]